Download PDF
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(08): E1186-E1187
DOI: 10.1055/a-1393-5780
Editorial

Follow-up after EUS-guided radiofrequency ablation for pancreatic lesions: With more answers, come more questions

Ryan Law
Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States
,
Michael J. Levy
Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Radiofrequency ablation (RFA) is a recently described technology for the treatment of low-grade pancreas lesions, such as neuroendocrine tumors (NETs) and pancreatic cystic neoplasms (PCNs). Early data suggest that this intervention is safe and effective; however, numerous questions remain regarding its role in our therapeutic armamentarium. RFA employs electromagnetic energy and high-frequency alternating currents to induce coagulative necrosis and fibrotic changes in highly thermosensitive tissues, such as the pancreas [1] [2] [3] This method of cell death causes the release of intracellular antigens known to stimulate a delayed immune response as well [4]. To date, a paucity of studies have examined the utility of RFA in treating pancreas lesions, and data on long-term outcomes are non-existent.



Publication History

Article published online:
16 July 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Refers to:

Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasmsEndosc Int Open 2021; 09(08): E1178-E1185
DOI: 10.1055/a-1479-2199

 

  • References

  • 1 Chaudhary S, Sun SY. Endoscopic ultrasound-guided radiofrequency ablation in gastroenterology: New horizons in search. World J Gastroenterol 2017; 23: 4892-4896
    CrossrefPubMedGoogle Scholar
  • 2 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7: 52-59
    CrossrefPubMedGoogle Scholar
  • 3 Lakhtakia S, Seo DW. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc 2017; 29: 486-494
    CrossrefPubMedGoogle Scholar
  • 4 Barthet M, Giovannini M, Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019; 51: 836-842
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Slovak R, Ludwig JM, Gettinger SN. et al. Immuno-thermal ablations – boosting the anticancer immune response. J Immunother Cancer 2017; 5: 78
    CrossrefPubMedGoogle Scholar
  • 6 Barthet M. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumor and pancreatic cystic neoplasms. Endoscopy International Open 2020; 09: E1178-E1185
    PubMedGoogle Scholar